RNA Interference from Biology to Therapeutics

Kenneth Alan Howard is an Associate Professor and Group Leader at the Department of Molecular Biology at the Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark. His team is based in a highly interdisciplinary setting with research and teaching activities focused on advanced drug delivery, nanomedicine, RNA interference, and inflammation. Dr Howard is CEO of an Aarhus University spin-out company that provides delivery solutions for RNA interference-based therapeutics. Kenneth Alan Howard received a PhD in Pharmaceutical Science from the University of Nottingham, UK in 1995, and has held postdoctoral positions at the CRC Institute for Cancer Studies, University of Birmingham, UK and the School of Pharmacy, University of London. Dr Howard is an active member of the Controlled Release Society serving on the Board of Scientific Advisors (chair), Nominations Committee and organizer of a CRS Educational workshop “RNA Interference Biology and Therapeutics”.

• RNA Interference Pathways and Therapeutic Exploitation RNA Interference.- Synthetic Dicer-Substrate siRNAs as Triggers of RNA Interference.- The Role of MicroRNAs in Natural Tissue Development and Application in Regenerative Medicine.- Intracellular Delivery Considerations for RNAi Therapeutics.- Mucosal Delivery of RNAi Therapeutics.- Nanomedicines for Systemic Delivery of RNAi Therapeutics.- Lipidoids: A Combinatorial Approach to siRNA Delivery.- Polymeric Micelles for siRNA Delivery.- RNAi Therapeutic Delivery by Exosomes.- Aptamer-Mediated siRNA Targeting.- RNAi as Anti-Viral Therapy: The HIV-1 Case.- Genome-Wide RNAi Screen for Identification of Human Host Factors Crucial for Influenza Virus Replication.- The Application of microRNAs in Cancer Diagnostics.- Therapeutic Application of miRNAs in Cancer.- Clinical Development of an Inhalable Anti-RSV siRNA Treatment.